Eluxadoline
As of the edition of 20 October 2026, Eluxadoline is a small molecule: marketed, first approved in 2015 (US); acts on OPRM1; US protection ends in 2029.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Small molecule
- Brand name
- Viberzi
- First approved
- 27 May 2015 (US)
- Approvals on record
- 4 in 2 regions
- Holder of the most recent approval
- AbbVie
- Withdrawn from market
- 18 December 2020 (in some regions)
- Registered trials
- 8, 2 stopped early
- Disease areas
- Digestive system; Hormones; Mental health; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive
US protection
US protection ends in 2029.
The last listed US drug-substance patent ends in 2029. The application that gives this date is held by AbbVie.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product6 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 6 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Eluxadoline.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| OPRM1 | Mu-type opioid receptor | P35372 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 2 | 0 | 1 |
| Phase 3 | 4 | 2 | 1 | 1 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 8 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Acquired holder and Lead sponsor of trials | 2017 to now |